Strategic Guide to Stability Testing of Biopharmaceutical Combination Products

Combination products—those that integrate a biologic with a device component—represent a growing segment in the pharmaceutical landscape. These include autoinjectors, prefilled syringes (PFS), on-body injectors, and inhalable biologics. Stability studies for such products are inherently complex, requiring simultaneous evaluation of drug integrity and device performance. This tutorial outlines the strategic, technical, and regulatory approaches to designing robust stability programs for biopharmaceutical combination products.

What Are Combination Biologic Products?

A combination product comprises two or more regulated components—typically a drug (biologic) and a device—physically, chemically, or otherwise combined to be used together. Common examples in the biopharma space include:

• Monoclonal antibodies in prefilled syringes or autoinjectors
• Insulin pens and cartridges
• PEGylated biologics in wearable infusion devices
• Implantable devices eluting cytokines or peptides

Why Stability Testing Is Challenging for Combination Products

Unlike standalone drug products, combination products present additional challenges such as:

• Interaction between drug and device materials (e.g., rubber, silicone, adhesives)
• Drug degradation due to extractables and leachables (E&L)
• Impact of storage conditions on mechanical or electronic components
• Need for functionality testing alongside chemical and microbiological testing
• Multiple regulatory jurisdictions (CDER + CDRH for FDA)

A well-designed stability study must address both pharmaceutical and engineering risks across the product’s lifecycle.

Regulatory Guidance on Combination Product Stability

Regulatory agencies have issued specific frameworks for assessing combination product quality:

• FDA 21 CFR Part 4: Applies CGMPs to combination products
• FDA Guidance: Current Good Manufacturing Practice for Combination Products
• ICH Q5C: Stability Testing of Biotech/Biological Products (drug portion)
• ISO 11608 Series: Functional requirements for needle-based injection systems
• USP , , , : Packaging, extractables, and leachables

Both drug and device components must be tested under unified stability protocols with appropriate acceptance criteria.

Step-by-Step Approach to Designing Stability Studies

Step 1: Define the Product Configuration and Use-Case

Start by defining the combination product structure:

• Primary container (e.g., glass syringe, polymer cartridge)
• Device interface (e.g., plunger, needle, auto-injection mechanism)
• Delivery method (manual vs. electronic vs. wearable)

Consider the intended use, number of actuations, and dose delivery per use to inform the stability design.

Step 2: Establish Storage Conditions and Test Timepoints

Use ICH-recommended conditions unless otherwise justified:

• Long-term: 2–8°C for refrigerated products, 25°C/60% RH for ambient
• Accelerated: 40°C/75% RH for up to 6 months

Test timepoints may include 0, 3, 6, 9, 12, 18, and 24 months based on proposed shelf life. Include in-use stability if applicable (e.g., product used multiple times after opening).

Step 3: Evaluate Drug Stability in Final Configuration

Use stability-indicating methods to assess biologic integrity within the device:

• Potency: Bioassays, ELISA
• Purity: CE-SDS, HPLC
• Aggregation: SEC, DLS
• Sub-visible particles: MFI, HIAC
• pH, osmolality, appearance

Test the product in the actual configuration it will be distributed and used (e.g., pre-assembled syringe with needle shield).

Step 4: Conduct Extractables and Leachables Studies

Device materials (elastomers, adhesives, lubricants) may leach into the biologic over time. Conduct E&L testing per USP /:

• Simulate storage and use conditions (thermal, humidity, light)
• Analyze leachables using GC-MS, LC-MS, ICP-MS
• Compare against safety thresholds (e.g., TTC, PDE)

Perform risk-based toxicological evaluation of detected leachables.

Step 5: Test Mechanical Functionality Under Stability Conditions

Device functionality must remain within specification over shelf life. Include tests such as:

• Plunger glide force, break-loose force
• Injection time and dose accuracy
• Needle deployment/retraction mechanisms
• Electronic actuation performance (for digital or wearable devices)

Perform function testing at each timepoint under ICH conditions.

Step 6: Assess Container Closure Integrity (CCI)

Especially critical for sterile injectable products. Use deterministic methods like:

• Vacuum decay
• Helium leak detection
• High-voltage leak detection (HVLD)

Confirm microbial ingress protection across time and storage conditions.

Step 7: Include In-Use Stability (If Applicable)

For products used over multiple doses or requiring reconstitution before use:

• Simulate puncture and dose withdrawal
• Store under recommended in-use conditions (e.g., 2–8°C post-opening)
• Test for potency, sterility, and microbial limits

Packaging Considerations in Combination Products

Materials such as glass, cyclic olefin polymers (COP), and elastomers must be compatible with biologics. Evaluate:

• Adsorption of protein to surfaces
• Silicone oil migration and interaction with active ingredient
• Metal ions from crimp or needle components

Choose container materials based on formulation pH, ionic strength, and protein concentration.

Case Study: Autoinjector Stability for a PEGylated Biologic

A PEGylated interferon biologic was developed in a 1 mL autoinjector system. Stability testing included 0–24 months at 2–8°C and 0–6 months at 40°C. Results showed no potency loss or aggregation. Leachables analysis confirmed sub-threshold levels of cyclic olefins and adhesives. Glide force testing passed at all intervals. The device met FDA expectations for combination product submission, and shelf life of 24 months was approved with the delivery system.

Checklist: Combination Product Stability Study Design

1. Define the complete drug-device configuration and intended use
2. Use ICH-aligned storage conditions and stability timepoints
3. Evaluate drug integrity in final assembled container
4. Conduct E&L studies and toxicological assessments
5. Perform mechanical function testing at each stability point
6. Verify container closure integrity and sterility
7. Align documentation with Pharma SOP and CTD Module 3

Common Mistakes to Avoid

• Testing the drug in bulk instead of in the final device configuration
• Overlooking mechanical or electronic device stability
• Delaying E&L testing until after design finalization
• Neglecting in-use simulation for products requiring dose withdrawal

Conclusion

Combination products demand an integrated stability strategy that accounts for drug quality, device reliability, and patient safety. By aligning biologic and engineering principles under a unified stability protocol, manufacturers can de-risk development and meet stringent global regulatory standards. For validated templates, integrated test plans, and regulatory-aligned SOPs, visit Stability Studies.